Rigel Pharmaceuticals (RIGL) Tops Q2 EPS by 67c; Offers Guidance
Tweet
Share
E-mailGet Alerts RIGL Hot Sheet
Price: $47.18 -3.06%
EPS Growth %: -34.9%
Financial Fact:
Interest income: 110K
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: -34.9%
Financial Fact:
Interest income: 110K
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Rigel Pharmaceuticals (NASDAQ: RIGL) reported Q2 EPS of $0.88, $0.67 better than the analyst estimate of $0.21. Revenue for the quarter came in at $78.7 million versus the consensus estimate of $54.94 million.
GUIDANCE:
Rigel Pharmaceuticals sees FY2026 revenue of $285-295 million, versus the consensus of $278.9 million.
For earnings history and earnings-related data on Rigel Pharmaceuticals (RIGL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Activist investor presses Xerox to review financial services arm - Bloomberg
- Stryker (SYK) Falls with Conf Ongoing
- eXoZymes Selects Curia as Commercial-Scale Manufacturing Partner for NCT
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
